DT 202
Alternative Names: DT-202Latest Information Update: 13 Oct 2022
At a glance
- Originator Dystrogen Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Graft-versus-host disease
Most Recent Events
- 06 Oct 2022 Early research in Graft-versus-host disease in USA (Parenteral) (Dystrogen Therapeutics pipeline, October 2022)